Celgene awarded key patent for attention deficit drug.Celgene Corporation (Warren, NJ; 732-271-1001) has been awarded United States Patent 5,908,850, which covers methods of treatment for attention deficit disorder attention deficit (hyperactivity) disorder (ADD or ADHD) formerly hyperactivity Behavioral syndrome in children, whose major symptoms are inattention and distractibility, restlessness, inability to sit still, and difficulty concentrating on one thing for any with the company's version of a chirally pure version of RITALIN (d-methylphenidate). The patent covers claims for use of the drug for the treatment of attention deficit disorder and attention deficit hyperactivity disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. . Multicenter studies are underway to evaluate different dosages, therapeutic benefits and the potential for reduced side effects Side effects Effects of a proposed project on other parts of the firm. of the Celgene pharmaceutical. Celgene also reported that the pivotal clinical trials designed to demonstrate efficacy of the d-methylphenidate product are fully enrolled. The trials are being conducted by leading investigators at 18 centers throughout the United States Celgene anticipates completion of the trials this year. "This patent is a major milestone in our chiral chi·ral adj. Of or relating to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image. chi·ral program, and greatly enhances our proprietary position in the marketplace," said Sol Barer, PhD, president and COO of Celgene. Celgene is also developing a "pulse release" formulation of d-methylphenidate. Initial clinical trials of the "pulse release" formulation are scheduled to commence later this year. Celgene was assigned a broad United States patent on the "pulse release" formulation of both d-methylphenidate and the racemate racemate Mixture of equal quantities of two enantiomers, substances whose molecular structures are mirror images of one another (see isomer). The two enantiomers rotate polarized light through opposite angles, canceling each other out so that the racemic mixture has late last year. Approximately one million American children are currently treated for attention deficit hyperactivity disorder, a figure that represents only a portion of those thought to suffer from the disease. Total North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. sales of dl-methylphenidate are estimated to exceed $400MM/year. Celgene is engaged in the development of pharmaceuticals and agrochemicals. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion